Sheet 1	of 1									
INFORMATION DISCLOSURE		ATTY. DOCKET NO.			SERI	4 N9./	5011	15		
		620-390		unknown						
		APPLICANT BRUINVELS		JC05 Rec'd PCT/PTO 21 SEP 2009						
										(Use
•		September 21, 2		2005 unknown						
•										
*EXAMINER		U.	S. PATENT I	DOCUMENTS				FILING	DATE	
INITIAL	DOCUMENT NUMBER	DATE		NAME		CLASS	SUBCLASS			
7S.M./	6,335,371 B1	01/2002	N	MAKI-IKOLA		ļ				
						. 				
						+			<u> </u>	
										
			 :			<u> </u>				
						ļ				
		FORI	EIGN PATEN	T DOCUMENTS						
•	DOCUMENT	DATE		COUNTRY		CLASS	SUBCLASS	TRANS YES	LATION NO	
/S.M./	01/96328 A1	12/2001		WO		1	000000.00		T	
/ <u>3.1VI./</u>	0 470 039 A2	02/1992		EP						
Ψ	03/091250 A1	11/2003		WO .		<u> </u>				
							·	 -		
		<u> </u>	·				ļ		 	
	OTUED DOOL	IMENITO (in	alicalina Arith	or, Title, Date, P	ortinant	pages of	20.		<u> </u>	
								-		
/C.N./	International Search Report of PCT/GB2004/001225, mailed 17 September 2004 SODHI et al., "Epigenetic influences on the serotonin2c (5-HT2c) receptor in psychiatric disorders", Society for									
/S.M./	Neuroscience Abstract Viewer and Itinerary Planner, Vol. 2003, Abstract No. 317.4, XP011822237									
1	MARCHESE et al., "Different 5-HT2A/2C antagonists impair dopamine re-uptake in the rat brain: role in catalepsy",									
Society for Neuroscience Abstracts, Vol. 26, No. 1-2, 2000, Abstract No271.13, XP00182407 WOOD et al., "5-HT2C receptor antagonists: Potential in schizophrenia", Drug Development Research, Vol. 26, No. 1-2, 2000, Abstract No271.13, XP00182407							Vol. 54,	No. 2,		
	October 2001, Pgs. 88-94, XP009032839									
	DI MATTEO et al, "SB 242 084, A Selective Serotonin2C Receptor Antagonist, Increases Dopaminergic Transmiss								nission in	
	the Mesolimbic System", Neuropharmacology, Vol. 38, No. 8, August 1999, Pgs. 1195-1205, XP000985700 BONACCORSO et al., "SR46349-B, a 5-HT2A/2C receptor antagonist, potentiates haloperidol-induced dopamine relea									
	in rat medial prefrontal cortex and nucleus accumbens", Neuropsychopharmacology, Vol. 27, No. 3, September 2002, Pgs. 430-441, XP002288018 KURTZ et al., "Therapy of schizophrenic patients with negative symptoms. Neuroleptic agents of the new generation Psychopharmakotherapie, 1996, Vol. 3, No. 2, 1996, Pgs. 57-65, XP009033022 MELTZER, "The role of serotonin in antipsychotic drug action", Neuropsychopharmacology, Vol. 21, No. 2, Augus 1999, Pgs. 106S-115S, XP002288019									
									ation",	
									pust	
	SCHERER et al., "Effect of a combination of flupentixol and nefazodone on negative, positive, and depressive symptoms									
	in schizophrenic patients	n schizophrenic patients. Six case reports", Psychopharmakotherapie 2000, Vol. 7, No. 2, Pgs. 82-86, XP009033549 RIEDEL et al., "Ziprasidone: A new atypical antipsychotic – Results from clinical trials", Psychopharmakotherapie 2002,								
V	Vol. 9, No. 3, Pgs. 85-94, XP009033548									
	1			!	. 1	00/04/1				
*Examiner	/Stacey Mac	farlane/		Date Consider	red	08/01/2	2007			

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.